Table 4.

Multivariate analysis of the factors associated with dispensation of celecoxib and rofecoxib versus traditional nonselective NSAIDs

	Celecoxib	Rofecoxib
Age group
75+	5.34 (4.96–5.75)	3.06 (2.83–3.30)
55 to ≤74	3.65 (3.45–3.87)	2.62 (2.46–2.78)
18–54	Reference	Reference
Female sex	1.55 (1.47–1.62)	1.45 (1.38–1.52)
Income level (lower)	0.95 (0.88–1.02)	0.83 (0.77–0.89)
Prior diagnosis of gastropathy	1.21 (1.07–1.37)	1.11 (0.97–1.27)
Prior gastrointestinal procedures	1.21 (1.02–1.42)	0.97 (0.81–1.16)
Prior dispensation of gastroprotective agents	1.59 (1.48–1.71)	1.51 (1.41–1.63)
Prior referral to gastroenterologist	1.27 (1.11–1.45)	1.19 (1.03–1.37)
Prior history of NSAID use:
Recent, first time	2.25 (1.99–2.54)	2.02 (1.79–2.29)
Recent, chronic	1.68 (1.52–1.85)	0.75 (0.68–0.84)
>1 to 3 months	1.36 (1.26–1.45)	0.48 (0.44–0.52)
>3 to 12 months	0.85 (0.80–0.91)	0.81 (0.76–0.87)
No use in past year	Reference	Reference
Corticosteroids	1.11 (1.02–1.20)	1.20 (1.11–1.31)
Anticoagulants	1.61 (1.34–1.94)	1.48 (1.23–1.78)
Antidepressants	1.38 (1.28–1.48)	1.37 (1.27–1.48)
Benzodiazepines	1.18 (1.12–1.25)	1.15 (1.09–1.22)
Acetaminophen	1.39 (1.31–1.48)	1.37 (1.28–1.45)
Low-dose ASA	0.67 (0.62–0.71)	0.58 (0.54–0.62)
Chronic Disease Score
10+	1.26 (1.11–1.43)	1.20 (1.06–1.37)
5–9	1.28 (1.19–1.38)	1.23 (1.14–1.33)
1–4	1.25 (1.17–1.33)	1.26 (1.18–1.34)
0	Reference	Reference
Physician specialty	0.96 (0.90–1.03)	0.83 (0.77–0.89)
Dosage
High dose	3.36 (3.15–3.58)	0.76 (0.70–0.82)
Low dose	0.09 (0.09–0.10)	0.73 (0.69–0.78)
Standard dose	Reference	Reference
Time period
January–June	1.25 (1.16–1.34)	0.24 (0.22–0.26)
July–September	1.09 (1.00–1.19)	0.93 (0.87–1.01)
October–December	Reference	Reference

ASA, acetylsalicylic acid; NSAID, nonsteroidal anti-inflammatory drug.